Physician profile
Mohammad A Arain
NPI 1457386294
$3,301.99
in general payments reported to CMS, 2019-2025
17 companies · $463 in 2025
The $463 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $726 · 2020: $231 · 2021: $309 · 2022: $503 · 2023: $385 · 2024: $684 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,532.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,347.87 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $911.10 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $361.55 | 2023-2025 | Repatha |
| Tela Bio, INC. | $164.91 | 2019 | |
| Janssen Pharmaceuticals, INC | $128.48 | 2019 | |
| Smith+Nephew, INC. | $83.27 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $80.06 | 2019-2020 | |
| Karl Storz Endoscopy-America | $42.78 | 2019 | |
| Abbott Laboratories | $41.72 | 2019-2023 | Freestyle Libre 2 |
| Baudax Bio INC. | $29.08 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.14 | 2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $18.47 | 2024 | Entyvio |
| Mannkind Corporation | $15.26 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $14.59 | 2025 | |
| Philips North America LLC | $13.65 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $13.33 | 2019 | |
| Shield Therapeutics INC | $12.73 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Arain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.